Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
UK’s biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation) priority areas.
French yeast manufacturer Lesaffre acquires an equity stake in US biotech company Intralytix. Paying more than €15m, Lesaffre gains valuable insights into the development and commercialisation of bacteriophage-based products.
French Antabio receives funding by the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Including future milestone payments, Antabio is eligible for up to €7.6m for their treatment of chronic infections in cystic fibrosis patients.
French vaccines expert Valneva SE announced that the FDA has granted Fast Track designation for its Lyme borreliosis vaccine candidate VLA15.
After 3 years of collaboration Roche has ended a cancer deal with the Spanish biotech company Oryzon granting the rights to their cancer candidate ORY-1001.
Belgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth €2.4bn but comes with an upfront payment of just €23m. The partners will initially focus on therapeutics for the treatment of various immune-mediated inflammatory diseases.
Swiss biopharmaceutical company Novimmune grants pharma company Shire a worldwide license to develop and commercialise a pre-clinical bispecific antibody candidate for haemophilia A.
The UK government has set up a new fund to support medical innovation. Breakthrough innovations that have the potential to benefit the NHS will also undergo accelerated access review aimed at speeding up access to novel medicines.
Following a safety warning of the EMA on deaths related to Biogen’s multiple scleroisis (MS) drug Zinbryta (daclizumab), German regulatory authority has issued a red hand letter.